👉Data from the ACOSOG Z0011 trial suggests completion axillary dissection can be avoided for small cancers with clinically node-negative, sentinel node (SN)-positive disease, provided that systemic therapy and whole-breast irradiation (WBI) are incorporated into the treatment strategy for early-stage breast cancer following breast-conserving surgery (BCS).
👉This trial took clinically node-negative patients with 1 to 2 positive SNs by hematoxylin and eosin staining who were treated with BCS and whole-breast irradiation and assigned them into 1 of 2 arms:
👉One that received completion ALND versus the other that received only SLNB.
👉The 10-year overall survival in the SLNB only group versus the completion ALND group was 86.3% and 83.6%, respectively.
👉Similarly, disease-free survival was 80.2% and 78.2%, respectively.
👉The study demonstrated that the 10-year in-breast recurrence rate was higher in the ALND group, 5.6% versus 3.8% (P=0.13) than in the sentinel lymph node resection only group.
👉Regional recurrence occurred in less than 1.5% of patients in both arms.
REFERENCES
Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.Ann Surg. 2010;252:426-432.
My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida.
I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016.
Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida.
Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.
View all posts by Rodrigo Arrangoiz MS, MD, FACS, FSSO
Rodrigo Arrangoiz MS, MD, FACS, FSSO 